RVXCF (Resverlogix) Retained Earnings : $-470.06 Mil (As of Dec. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Resverlogix Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Resverlogix's retained earnings for the quarter that ended in Dec. 2024 was $-470.06 Mil.

Resverlogix's quarterly retained earnings declined from Jun. 2024 ($-465.59 Mil) to Sep. 2024 ($-470.53 Mil) but then increased from Sep. 2024 ($-470.53 Mil) to Dec. 2024 ($-470.06 Mil).

Resverlogix's annual retained earnings declined from Dec. 2022 ($-445.69 Mil) to Dec. 2023 ($-462.43 Mil) and declined from Dec. 2023 ($-462.43 Mil) to Dec. 2024 ($-470.06 Mil).

Resverlogix Retained Earnings Historical Data

The historical data trend for Resverlogix's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Resverlogix Retained Earnings Chart

Resverlogix Annual Data

Trend

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Dec21

Dec22

Dec23

Dec24

Retained Earnings

Get a 7-Day Free Trial

-418.95

-442.08

-445.69

-462.43

-470.06

Resverlogix Quarterly Data
	Jan20	Apr20	Jul20	Oct20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Retained Earnings	Get a 7-Day Free Trial															-462.43	-461.09	-465.59	-470.53	-470.06

Resverlogix Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Resverlogix (OTCPK:RVXCF) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Resverlogix Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Resverlogix Corp (OTCPK:RVXCF) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

RVX:Canada

Address

4820 Richard Road South West, Suite 300, Calgary, AB, CAN, T3E 6L1

Website

https://www.resverlogix.com

Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.